Uppsala, Sweden - September 5, 2017 - Orexo AB, together with Malmö University and two other industry partners, Nanologica AB and Clinical Trial Consultants AB (CTC), has received a research grant of SEK 2.4 million from The Knowledge Foundation for research on nanoporous silicon dioxide particles for pharmaceutical formulations. The research will primarily be conducted at Biofilms - Research Center for Biointerfaces (BRCB) at Malmö University and aims to systematically evaluate nanoporous silicon dioxide particles as pharmaceutical drug carriers.
“We are very pleased with the research grant received from The Knowledge Foundation and are looking forward to the collaboration with the researchers at BRCB, Nanologica and CTC. Nanoporous silicon dioxide particles have the potential to improve the properties of pharmaceutical formulations and align well with our efforts to develop next generation drug delivery technologies." - Robert Rönn, PhD, Head of Pharmaceutical Development and IP, Orexo AB
For more information please contact firstname.lastname@example.org